Centiva Capital LP Takes $120,000 Position in Altimmune, Inc. (NASDAQ:ALT)

Centiva Capital LP acquired a new position in Altimmune, Inc. (NASDAQ:ALT) during the third quarter, HoldingsChannel.com reports. The fund acquired 19,607 shares of the company’s stock, valued at approximately $120,000.

Other large investors have also added to or reduced their stakes in the company. Larson Financial Group LLC bought a new position in Altimmune in the third quarter valued at approximately $31,000. Horizon Wealth Management LLC bought a new stake in shares of Altimmune during the 2nd quarter worth approximately $66,000. PFG Investments LLC acquired a new stake in shares of Altimmune in the 2nd quarter valued at approximately $67,000. Principal Financial Group Inc. bought a new position in shares of Altimmune in the second quarter valued at $70,000. Finally, Verus Capital Partners LLC acquired a new position in Altimmune during the second quarter worth $82,000. Institutional investors and hedge funds own 78.05% of the company’s stock.

Altimmune Price Performance

NASDAQ:ALT opened at $9.03 on Friday. The company has a market cap of $642.26 million, a P/E ratio of -5.83 and a beta of 0.15. The firm’s fifty day moving average price is $7.71 and its two-hundred day moving average price is $7.06. Altimmune, Inc. has a one year low of $5.28 and a one year high of $14.84.

Altimmune (NASDAQ:ALT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping the consensus estimate of ($0.35) by $0.03. The business had revenue of $0.01 million during the quarter. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. During the same period in the previous year, the firm posted ($0.39) EPS. As a group, equities research analysts expect that Altimmune, Inc. will post -1.36 earnings per share for the current year.

Wall Street Analyst Weigh In

ALT has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, November 14th. UBS Group began coverage on shares of Altimmune in a research note on Tuesday, November 12th. They issued a “buy” rating and a $26.00 target price for the company. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Altimmune currently has an average rating of “Moderate Buy” and an average price target of $20.00.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.